SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: AHM who wrote (674)6/30/1998 9:01:00 PM
From: Robert Knight  Read Replies (1) of 1510
 
Very good point about today being the last day of the quarter for the institutional crowd. Some very well could have locked in some profit or take some chips off of the table after the gains from 10.

How about this from the MF Evening report....

> Several pharmaceutical companies offering anti-HIV treatments fell today after The Wall Street Journal reported that DuPont's (NYSE: DD) not-yet-approved Sustiva drug could simplify the so-called "AIDS cocktails" used to treat the disease. The drug, a non- nucleoside reverse transcriptase inhibitor, could be combined with
Glaxo Wellcome's (NYSE: GLX) Combivir reverse transcriptase drug,
which is a combination of the better known anti-HIV drugs AZT and
3TC. The article suggests that the new combination could wipe out
the need for another class of drugs called protease inhibitors.
While any development that may ease the suffering of HIV patients
is definitely worth investigating, investors should keep in mind
that researchers are still holding out the hope that all of the
various anti-HIV drugs will be rendered unnecessary at some point
on the development of an effective vaccine. In the meantime, Vertex Pharmaceuticals (Nasdaq: VRTX), which develops protease inhibitors, fell $5 1/8 to $22 1/2, while rival Agouron Pharmaceuticals (Nasdaq: AGPH) slid $3 1/16 to $30 5/16.<<<<

Robert
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext